Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00461045 · OUTCOME

Maximum Observed Blood Drug Concentration (Cmax)

Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma · Source last updated 2017-12-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Samples collected on Cycle 1 Day 1 and Cycle 1 Day 11.

Analysis population: The sponsor elected not to analyze the pharmacokinetic (PK) samples collected, therefore, no PK results are obtained.

Groups in this outcome

MRZ 0.5 mg/m^2

Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
MRZ 0.5 mg/m^20

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
groups
  1. description
    Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles
    id
    OG000
    title
    MRZ 0.5 mg/m^2
population Description
The sponsor elected not to analyze the pharmacokinetic (PK) samples collected, therefore, no PK results are obtained.
reporting Status
POSTED
time Frame
Samples collected on Cycle 1 Day 1 and Cycle 1 Day 11.
title
Maximum Observed Blood Drug Concentration (Cmax)
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice